Companies

Granules India gets USFDA nod for Metformin Hydrochloride tablets

Our Bureau Hyderabad | Updated on January 13, 2021 Published on January 13, 2021

Drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; had US sales of about $192 mn for 12 months ending November 2020

Granules India Limited has received final approval from the US Food & Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Metformin Hydrochloride Extended-Release Tablets, generic equivalent of Glumetza ER Tablets of Bausch Health US LLC (Bausch).

Metformin Hydrochloride ER Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Also read: Granules gets USFDA’s nod for Penicillamine Capsules

Metformin Hydrochloride ER Tablets had US sales of approximately $192 million for the most recent 12 months ending in November 2020, according to IQVIA Health.

Granules now has a total of 35 ANDA approvals from US FDA (34 final approvals and one tentative approval).

Glumetza is a trademark of Salix Pharmaceuticals, Inc. or its affiliates, the Hyderabad-based Granules said in a release.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 13, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.